Spectrum and Steribottle partner for saliva-based Covid-19 testing

Spectrum Solutions and Steribottle have partnered for the Covid-19 population testing directive in the UK that integrates the former’s SDNA-1000 Saliva Collection Device.

The implementation of the extensive country-wide testing mandate will include every UK citizen once a week.

The company noted that saliva-based tests can quickly increase access and testing options in order to fight Covid-19 in the UK.

Spectrum Solutions president and CEO Stephen Fanning said: “Even with new vaccines, it is more important than ever before to increase the rate of testing.

“It is vital to global health and safety for individuals and governments to be aware of accurate infection rates and geographic hot spots in order to plan and execute effective healthcare strategies and initiatives.”

The Spectrum Solutions’ SDNA-1000 Saliva Collection Device is the first saliva-based solution to receive emergency use authorisation (EUA) from the US Food and Drug Administration (FDA) for Covid-19 testing.

The easy-to-use option does not require using painful nasal swab processes to provide a precise and pain-free saliva collection process.

Engineered to eradicate user collection errors and deliver a path for at-home self-collection of the sample, it can eliminate the risk of being exposed to the virus with the in-device viral inactivation.

Apart from providing the safest and robust biomaterial for detecting Covid-19, the system offers more than ten days of post-collection stability without degrading the sample efficacy.

Steribottle CEO Luke Fisher said: “The Spectrum saliva-based testing solution provides a validated system and proven process that safely mitigates unnecessary exposure.”

Separately, Spectrum Solutions received CE Mark approval to sell and distribute its SDNA saliva collection devices to conduct IVD molecular diagnostic testing in Europe.